SMA RT CONTROL AND SMART VASCULAR STENT SYSTEMS
Cordis US Corporation · Decision date Nov 7, 2012
What did the FDA approve?
FDA approved the S.M.A.R.T. Control and S.M.A.R.T. Vascular Stent Systems on November 7, 2012. The stated purpose is to improve luminal diameter in patients with de novo or restenotic native lesions of the superficial femoral artery and/or proximal popliteal artery, where total lesion length is up to 150 mm and reference vessel diameter ranges from 4 mm to 7 mm.
The decision is an original PMA approval for Cordis US Corporation under product code NIP, classified as a superficial femoral artery stent. The statement reports the device's indicated use; it does not independently establish safety or clinical effectiveness. No supplement type or reason is recorded, so no change to a prior approval is described.
FDA approval order statement
APPROVAL FOR THE S.M.A.R.T. CONTROL AND S.M.A.R.T. VASCULAR STENT SYSTEMS. THIS DEVICE IS INDICATED FOR USE TO IMPROVE LUMINAL DIAMETER IN THE TREATMENT OF PATIENTS WITH DE NOVO OR RESTENOTIC NATIVE LESION(S) OF THE SUPERFICIAL FEMORAL ARTERY AND/OR PROXIMAL POPLITEAL ARTERY WITH TOTAL LENGTH UP TO 150 MM AND WITH A REFERENCE VESSEL DIAMETER RANGING FROM 4 MM TO 7 MM.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 7, 2012
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120002
- Regulatory pathway
- Premarket approval application
- Applicant
- Cordis US Corporation
- Product code
- NIP
- Decision code
- APPR
- Decision date
- Nov 7, 2012
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Cordis US Corporation
- Product code
- NIP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P120002 received
Application receipt date recorded by FDA.
P120002 · FDA decision
APPR
P120002/S036 · Related supplement
S.M.A.R.T. and S.M.A.R.T. CONTROL Vascular Stent Systems; S.M.A.R.T. RADIANZ Vascular Stent System
Timeline entries are records held by MedtechLedger for P120002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cordis US Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 14201 NW 60th Ave., Miami Lakes, FL, 33014
Sources and methodology
- Original FDA record: P120002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


